Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug discovery program targeting ATR.
Rakovina Therapeutics has already integrated cutting-edge AI platforms, such as Deep Docking™ and Enki™, into its drug discovery programs. These technologies enable the company to analyze billions of ...